Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 2Phase 4 1Phase 2 1Phase 1/2 1

Status

Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 67Breast Neoplasms, Male 4Neoplasm Metastasis 3Neoplasms 2Advanced Breast Cancer 2Unilateral Breast Neoplasms 1Sleep Wake Disorders 1Recurrence 1Ovarian Neoplasms 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1First Line Metastatic Breast Cancer 1Fatigue 1Carcinoma, Intraductal, Noninfiltrating 1Bulbo-Spinal Atrophy, X-Linked 1Breast Carcinoma In Situ 1Breast Cancer Metastatic 1Breast Cancer Female 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × exemestane × Clear all
NCT04906395 2026-01-13

OVELIA

Tolmar Inc.

Phase 3 Active not recruiting
250 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Tolmar Inc.

Phase 3 Enrolling by invitation
250 enrolled
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡